This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
EMA’s environmental management system has been certified with the Eco-Management...
CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus...
CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus...
At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad rang...
EMA, in close collaboration with the European Commission, has established a stan...
EMA has published an overview of its key recommendations of 2024 regarding the a...
In 2024, EMA recommended 114 medicines for marketing authorisation. Of these, 46...
EMA is ready to support the implementation of the new regulation on health techn...
EMA has published the revised version of its policies on the handling of competi...
Medicines containing semaglutide: PRAC investigating risk of rare eye conditionP...
CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus...
From today, all clinical trials in the European Union (EU), including ongoing tr...
EMA has recommended the approval of the vaccines Bluevac-3 and Syvazul BTV 3 to ...
EMA is celebrating 30 years of operations marking its evolving role at the centr...
The European Shortages Monitoring Platform (ESMP) is now live with the full scop...
For the first time, the five EU health and environment agencies – EFSA (European...
Eight new medicines recommended for approvalEMA’s human medicines committee (CHM...